title: Novel assay of competitively differentiated polymerase chain reaction for screening point mutation of hepatitis B virus.
abstract: OBJECTIVE
  Point mutation, one of the commonest gene mutations, is the most important molecular pathogenesis of cancer and chronic infection. The commonest methods for detection of point mutation are based on polymerase chain reaction (PCR). These techniques, however, cannot be used in large scale screening since they are neither accurate nor simple. For this reason, this study established a novel method of competitively differentiated PCR (CD-PCR) for screening point mutation in clinical practice.
  
  
  METHODS
  Two competitively differentiated primers for mutant-type and wild-type templates respectively with an identically complemented region in 3' end except for last 2 base pairs and a different non-complemented region in 5' end were designed. Thus, competitive amplification might be carried out at a lower annealing temperature at first, and then differentiated amplification at a higher annealing temperature when primers could not combine with initial templates. The amplification was performed in one-tube. The products of CD-PCR were detected using microplate hybridization assay. CD-PCR was evaluated by detecting G1896A variant of hepatitis B virus (HBV) in form of recombinant plasmids and in sera from patients with hepatitis B, and compared with allele-specific PCR (AS-PCR) and competitive AS-PCR.
  
  
  RESULTS
  CD-PCR was successfully established. It could clearly distinguish wild-type and mutant-type plasmid DNA of G1896A variant when the amount of plasmid DNA was between 10(2)-10(8)copies/reaction, while for AS-PCR and competitive AS-PCR, the DNA amount was between 10(2)-10(4)copies/reaction. CD-PCR could detect one copy of G1896A variant among 10-100 copies of wild-type plasmid DNA. The specificity of CD-PCR was higher than those of AS-PCR and competitive AS-PCR in the detection of HBV G1896A variant in sera from patients with hepatitis B. CD-PCR was independent of the amount of HBV DNA in serum. HBV G1896A variant was more often found in HBeAg (-) patients with a lower level of detectable viremia than that with a higher level of detectable viremia (P=0.0192).
  
  
  CONCLUSIONS
  CD-PCR is more specific since it is less influenced by the amount of initial templates and the cross amplification between mutant- and wild-type amplified products. It is also simple and time-saving. Thus, CD-PCR might be useful in routine gene typing and point mutation screening. HBV G1896A or other more important mutations have to be routinely detected in patients with a detectable level of viremia after HBeAg/antibody conversion in clinical practice.
authors.affiliation: Department of Infectious Diseases, the Third Affiliated Hospital, Zhongshan University, Guangzhou 510630, China. xiaomoupeng@hotmail.com
authors.forename: Xiao-Mou
authors.initials: XM
authors.lastname: Peng
authors.forename: Xue-Juan
authors.initials: XJ
authors.lastname: Chen
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: Gu
authors.forename: Yang-Su
authors.initials: YS
authors.lastname: Huang
authors.forename: Zhi-Liang
authors.initials: ZL
authors.lastname: Gao
mesh_terms: D004279:DNA, Viral / Q000097:blood; D005820:Genetic Testing; D014644:Genetic Variation; D006515:Hepatitis B virus / Q000235:genetics*; D006801:Humans; D010957:Plasmids / Q000235:genetics; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000379:methods
chemical_list: D004279:DNA, Viral